脏移植和他类药物对接受脏移植的患者的失脂症的影响
Ziad Arabi1,2,3, Mohammed Tawhari1,2,3, Tarek Arabi4
1Division of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Annals of medicine and surgery (2012)
|November 3, 2025
概括
移植 (KTx) 改善了HDL和TG水平,但增加了LDL和TC. 类药物有助于维持这些益处,并防止沙特KTx接受者的不良脂质变化.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 失脂症在移植接受者 (KTRs) 中普遍存在,影响高达75%的患者.
- 类药物经常用于管理移植后的脂质水平.
- 有限的研究存在于KTRs中基于塔克罗利斯的疗法对失脂症和他类药物的影响,特别是在中东.
研究的目的:
- 调查移植 (KTx) 对沙特KTRs脂质样本的影响.
- 评估他类药物在治疗KTx后性脂质失调症中的作用,在基于塔克罗利斯的免疫抑制方案中.
主要方法:
- 从2017年到2020年,对287个KTR进行了回顾性分析.
- 脂质样本和HbA1c水平在KTx前和12个月后的比较.
- 基于在KTx后的第一年使用他类药物的患者分层.
主要成果:
- 单独KTx增加了总胆固醇 (TC) 和低密度脂蛋白 (LDL),但也改善了高密度脂蛋白 (HDL) 和降低了甘油三 (TGs).
- 在KTR中使用静止剂显著改善了HDL水平和降低了TG水平.
- 静止剂使用者与非使用者不同,在TC或LDL中没有显著变化,尽管体重增加和HbA1c升高相似.
结论:
- 尽管对体重和HbA1c有潜在的不良影响,但KTx对HDL和TG水平产生了积极的影响.
- 立方体治疗对KTRs至关重要,保留KTx对HDL/TG的有益作用,并减轻TC/LDL的增加.
- 静止剂的使用有效地调节后KTx脂质变化,在TACROLIMUS基于免疫抑制的患者.
相关概念视频
01:28Kidney Transplant I: Introduction
321
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
321
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:16Kidney Transplant III: Nursing Management
304
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
304
01:26Kidney Transplant II: Surgical Procedure
297
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
297
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
255
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
255
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
202
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
202